Cart
sales@molnova.com
(2R,3S,11bS)-Dihydrotetrabenazine
CAS No. 924854-62-6
(2R,3S,11bS)-Dihydrotetrabenazine( —— )
Catalog No. M36049 CAS No. 924854-62-6
(2R,3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-ol is an impurity of Tetrabenazine, which is a VMAT inhibitor used in the treatment of hyperkinetic movement disorder.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 107 | In Stock |
|
| 10MG | 158 | In Stock |
|
| 25MG | 236 | In Stock |
|
| 50MG | 324 | In Stock |
|
| 100MG | 442 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(2R,3S,11bS)-Dihydrotetrabenazine
-
NoteResearch use only, not for human use.
-
Brief Description(2R,3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-ol is an impurity of Tetrabenazine, which is a VMAT inhibitor used in the treatment of hyperkinetic movement disorder.
-
Description(2R,3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-ol is an impurity of Tetrabenazine, which is a VMAT inhibitor used in the treatment of hyperkinetic movement disorder.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number924854-62-6
-
Formula Weight319.44
-
Molecular FormulaC19H29NO3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[H][C@@]12C[C@@H](O)[C@@H](CC(C)C)CN1CCc1cc(OC)c(OC)cc21
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Citiolase
Citiolone is a thiolic-derived medication as a mucolytic agent for the treatment of certain hepatic disorders.
-
[Ile34]-β- Amyloid (...
[Ile34]-β- Amyloid (25 - 34)
-
(D-Arg1,D-Trp7·9,Leu...
Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation.
